Do not use TENMAC-EM for pre-exposure prophylaxis in individuals with unknown or positive HIV-1 status. TENMAC-EM should be used in HIV-infected patients only in combination with other anti-retroviral agents.
In HIV1 infected patients, the most common adverse reactions (incidence greater than or equal to 10%) are diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash. In HIV-1 uninfected individuals in PrEP trials, adverse reactions that were reported by more than 2% of TENMAC-EM subjects and more frequently than by placebo subjects were headache, abdominal pain and weight decreased.
HDPE Bottle packs of 30 tablets and packed in a unit carton along with package insert.
SHELF LIFE AND STORAGE: